Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandem High Dose Melphalan with PBSCT in Waldenstrom's Macroglobulinemia
NCT00003416Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 1998
- Primary completion
- Aug 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in Waldenstrom macroglobulinemia (WM), sponsored by SWOG Cancer Research Network. Primary endpoints: Confirmed Remission Rate, Overall Survival and 2 more. Started Sep 1998; status: completed.
02
Drugs
melphalan
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00003416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003416.